Last reviewed · How we verify
Low THC
At a glance
| Generic name | Low THC |
|---|---|
| Sponsor | University of California, Los Angeles |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Oral mucositis: Requiring intervention
- Febrile neutropenia
- Hypoxia: decreased O2 sat
- Febrile neutropenia: attributed to rATG
- Fever (not neutropenic): attributed to rATG
- Rash (>50%)
- Hypotension: requiring intervention
- Pancreatitis
- Seizure (conciousness altered)
- Elevated bilirubin (>3-10x ULN)
- Hemolysis (AIHA): Requiring transfusion and sterioids
- Epistaxis
Key clinical trials
- Cannabis Effects as a Function of Sex (PHASE1)
- AnalgeSiC and appEtite-stimulating Effects of caNnabigerol and THC (ASCENT) (PHASE1)
- Efficacy and Safety of VER-01 in the Treatment of Patients With Radicular Chronic Low Back Pain (PHASE3)
- Do Discounted Vouchers for Medical Cannabis Reduce Opioid Use in Adults With Pain (NA)
- Pregnenolone as a Treatment for Cannabis Intoxication (PHASE2)
- Behavioral Pharmacology of THC and Beta-Myrcene (PHASE1)
- Cannabinoids as a Treatment for Insomnia in Major Depression (PHASE2)
- Effect of Cannabis on Cigarette Use Behavior (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low THC CI brief — competitive landscape report
- Low THC updates RSS · CI watch RSS
- University of California, Los Angeles portfolio CI